Literature DB >> 15751057

Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.

Angelo Ravelli1, Enrico Felici, Silvia Magni-Manzoni, Angela Pistorio, Cristina Novarini, Elena Bozzola, Stefania Viola, Alberto Martini.   

Abstract

OBJECTIVE: We recently hypothesized that in the International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis (JIA), the presumably homogeneous patient group characterized by early onset of disease, a female predilection, the presence of antinuclear antibodies (ANA), asymmetric arthritis, and the risk for iridocyclitis is classified into different categories. We sought to investigate whether ANA-positive patients belonging to the ILAR categories of oligoarthritis and rheumatoid factor (RF)-negative polyarthritis share homogeneous features and to compare these features with those of ANA-negative patients with JIA in the same categories.
METHODS: We identified patients who were followed up during a 15-year period. All patients had JIA according to the ILAR criteria, with oligoarticular or polyarticular onset. ANA positivity was defined as 2 or more positive results at a titer of >or=1:160. Demographic and clinical features, including the number of joints involved over time and measures of JIA severity at the last followup visit, were recorded retrospectively.
RESULTS: A total of 256 patients were included: 190 were ANA positive (109 had persistent oligoarthritis, 48 had extended oligoarthritis, and 33 had RF-negative polyarthritis), and 66 were ANA negative (35 had RF-negative polyarthritis, and 31 had oligoarthritis). All patients who were positive for ANA were similar in terms of age at disease presentation, female-to-male ratio, and frequency of symmetric arthritis and iridocyclitis. Compared with ANA-positive patients with polyarticular disease, ANA-negative patients with polyarticular arthritis were older at disease presentation and had a lower frequency of iridocyclitis, a higher frequency of symmetric arthritis, a greater cumulative number of joints affected over time, and a different pattern of joint disease, with a greater frequency of shoulder and hip involvement. The strong relationship between the presence of ANA and younger age at disease presentation, asymmetric arthritis, and development of iridocyclitis was confirmed by multivariate regression analysis.
CONCLUSION: Our results support the hypothesis that patients with similar characteristics are currently classified into different JIA categories. The value of ANA positivity as a possible modifier of the current classification system deserves consideration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15751057     DOI: 10.1002/art.20945

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  55 in total

Review 1.  Juvenile idiopathic arthritis-associated uveitis.

Authors:  Ying Qian; Nisha R Acharya
Journal:  Curr Opin Ophthalmol       Date:  2010-11       Impact factor: 3.761

2.  Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis.

Authors:  Fasika Woreta; Jennifer E Thorne; Douglas A Jabs; Sanjay R Kedhar; James P Dunn
Journal:  Am J Ophthalmol       Date:  2006-12-20       Impact factor: 5.258

3.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

4.  Antinuclear Antibody-Positive Juvenile Idiopathic Arthritis Despite IRAK-4 Deficiency.

Authors:  Boris Hügle; Norman Händel; Klaus Schwarz; Michael Borte; Volker Schuster
Journal:  J Clin Immunol       Date:  2018-04-29       Impact factor: 8.317

5.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

6.  Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.

Authors:  Thomas A Griffin; Michael G Barnes; Norman T Ilowite; Judyann C Olson; David D Sherry; Beth S Gottlieb; Bruce J Aronow; Paul Pavlidis; Claas H Hinze; Sherry Thornton; Susan D Thompson; Alexei A Grom; Robert A Colbert; David N Glass
Journal:  Arthritis Rheum       Date:  2009-07

7.  Antinucleosome antibodies in juvenile chronic arthritis.

Authors:  Renato M Nisihara; Thelma Skare; Marilia Barreto Silva; Rafael Mourato Silva; Danilo J Munhoz Silva
Journal:  Clin Rheumatol       Date:  2009-09-30       Impact factor: 2.980

8.  Is high-resolution ultrasonography suitable for the detection of temporomandibular joint involvement in children with juvenile idiopathic arthritis?

Authors:  A T Assaf; B Kahl-Nieke; J Feddersen; C R Habermann
Journal:  Dentomaxillofac Radiol       Date:  2013       Impact factor: 2.419

Review 9.  The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.

Authors:  Melissa A Lerman; C Egla Rabinovich
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

10.  Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.

Authors:  Anthony C Gregory; John H Kempen; Ebenezer Daniel; R Oktay Kaçmaz; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.